G&A at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s G&A?
- Immunovant, Inc. (IMVT) reported G&A of $17.27M in Q1 2026.
- How has Immunovant, Inc.'s G&A changed year-over-year?
- Immunovant, Inc.'s G&A decreased by 14.4% year-over-year, from $20.17M to $17.27M.
- What is the long-term trend for Immunovant, Inc.'s G&A?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s G&A has grown at a 8.9% compound annual growth rate (CAGR), from $54.23M to $76.24M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.